AUTO-3 is under clinical development by Autolus Therapeutics and currently in the Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect AUTO-3’s likelihood of approval (LoA) and phase transition for B-Cell Acute Lymphocytic Leukemia (B-Cell Acute Lymphoblastic Leukaemia) took place on 18 Oct 2022, which increased the likelihood that the drug progresses to the next phase in its clinical pathway and increased the likelihood of final approval for this indication.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their AUTO-3 Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

AUTO-3 overview

AUTO-3 is under development for the treatment of primary mediastinal large B cell lymphoma, relapsed or refractory B-cell acute lymphoblastic leukemia in pediatrics and young adults and diffuse large B-cell lymphoma. It is administered as an intravenous infusion. It consists of patient’s own genetically modified T cells by CAR gene, that selective target and destroys cancer cells. It is developed based on engineered CAR T-cell technology. It acts by targeting CD19 and CD22.

Autolus Therapeutics overview

Autolus Therapeutics (Autolus), formerly Autolus Therapeutics is a clinical-stage biopharmaceutical company. It offers programmed T cell therapies for the treatment of hematological cancers and solid tumors. Autolus pipeline products includes Obe-cel, AUTO1/22, AUTO5, AUTO6NG, AUTO7 and AUTO8. It has also developed proprietary viral vector and semi-automated cell manufacturing processes, which are used in clinical-stage programs. The company collaborates with leading academic institutions and industry partners to develop and deliver programmed T cell product candidates for cancer patients. Autolus is headquartered in London, Greater London, the UK.

Quick View AUTO-3 LOA Data

Report Segments
  • Innovator
Drug Name
  • AUTO-3
Administration Pathway
  • Intravenous
Therapeutic Areas
  • Oncology
Key Developers
Highest Development Stage
  • Phase II

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.